Tuesday, 29 May 2018

Europe Scar Treatment Market - Recent Study Including Growth Factors, Applications, Key Players and Forecasts till 2023

The Europe scar treatment market size was valued at $5.2 billion in 2016, which is expected to reach $9.8 billion by 2023, growing at a CAGR of 9.6% during the forecast period (2017-2023). Topical scar treatment is expected to witness highest growth during the forecast period in the European scar treatment market due to increasing disposable income, rising prevalence of chronic wounds and availability of different types of topical scar treatment products. Topical scar treatment is followed by surface scar treatment, laser scar treatment,  injectable scar treatment, invasive surgical scar treatment. Among the different types of scar, post-surgical scar was the most widely treated type of scar in Europe in 2016, followed by acne scar, keloid scar & hypertrophic scar, contracture scar, and stretch mark. The contribution of hospital in the European scar treatment market was the highest in 2016 mainly due to continuously developing reimbursement structure in the region.

The key players in the European scar treatment market are coming up with scar treatment products with innovative technologies, especially with laser therapy approaches. For instance, in September 2015, Lumenis Ltd. Announced promising clinical data of its advanced laser platform, UltraPulse with SCAAR FX, at the 16th European Burns Association Congress, in Hannover, Germany. Laser scar therapy, especially fractional ablative laser resurfacing, has turned out to be a momentous advancement in scar treatment and management and has been increasingly adopted as a promising approach in the treatment of burns and scars.
Some of the key players operating in the European scar treatment market include Merz GmbH & Company KGAA, Mölnlycke Health Care AB, Smith & Nephew Plc, Syneron Medical Ltd., Lumenis Ltd., L'oreal S.A, H&R Healthcare Ltd., Avita Medical, Arbonne International, and Laverana GmbH & Co.KG.
About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Posted by at No comments:
Labels: , , , ,

Monday, 7 May 2018

Cancer Tumor Profiling Analysis, Market Key Players, Segmentation and Forecast to 2023

The cancer tumor profiling market in terms of technology has been segmented into next generation sequencing (NGS), quantitative polymerase chain reaction (QPCR), immunohistochemistry (IHC), in-situ hybridization (ISH), and microarray, based on technology. NGS held the largest share in the cancer/tumor profiling industry, standing at 33.1%, in 2016. This leading position of NGS is mainly characterized by increased awareness about NGS products due to rising promotional activities for these products among the research laboratories and academic institutes. The NGS category is also expected to grow at the highest CAGR during the forecast period.

 Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cancer-profiling-market/report-sample

The players in the market are developing different biomarkers based on what is to be detected in a patient. For instance, Caris Life Sciences, develops several biomarkers that are based on IHC, that detects the level of protein expression, translocations and fusions, ISH, amplifications, detects gene deletions, NGS, rapidly examines and more broadly detects DNA mutations, copy number variations and gene fusions across the genome, and fragment analysis, that detects changes in RNA or DNA to indicate the absence or presence of genetic marker. Due to this precise detection using biomarkers for the cancer-causing agent, there is an increase in the use of biomarkers for cancer profiling and thereby driving the growth of the cancer/tumor profiling market.

 The key players in the cancer/tumor profiling market are collaborating with other firms to expand their market share. In September 2017, Indivumed, GmbH and Helomics Corp. entered into a partnership to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world.

 Explore Report at: https://www.psmarketresearch.com/market-analysis/cancer-profiling-market

 Some of the other key players operating in the cancer/tumor profiling market include Illumina, Inc., NeoGenomics Inc., Caris Life Sciences, Inc., Oxford Gene Technology, HTG Molecular Diagnostics, Inc., RiboMed Biotechnologies, Inc., QIAGEN N.V. and NanoString Technologies, Inc.
About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Posted by at No comments:
Labels: , , ,

Protein Expression Market Trends, Size, Growth and Development Forecast to 2023

According to the study, the global protein expression market is likely to grow from $1.4 billion in 2016 to $3.0 billion by 2023. Major key players in the market are developing products with technically advanced features that are designed to produce high protein yield, maintaining a balance of speed and scalability, thereby enhancing its application in the drug development workflow.


Some of the recent advanced product launched by the major players in the market include Gibco ExpiCHO expression system, launched in 2015 by ThermFisher Scientific Inc., that offers an increase yield of over 100-fold, thereby enabling upto 3g/L of protein yield; in comparison to its previous CHO system. Therefore, technically advanced products are a major factor driving the growth of the market during the forecast period.

Geographically, North America has been the largest market for protein expression, with the U.S. being the larger contributor to the regional market, as compared to Canada. The dominant position of the North American market is mainly attributable to the rise in R&D infrastructure, increased aging population, rise in healthcare expenditure and increasing prevalence of chronic diseases in the region.


Increasing number of acquisitions is a key trend observed in the protein expression market. The key players globally are acquiring segments and/or companies to increase their share in the global market. In January 2017, Bio-Rad Laboratories, Inc. (Bio-Rad) acquired RainDance Technologies, Inc. (RainDance). As per the terms of acquisition, RainDance Technologies, Inc. offered its droplet-based solutions to Bio-Rad Laboratories, Inc. and has extended its reach into next generation sequencing applications. Similarly, Takara Bio USA Holdings, Inc. (“TBUSH”) acquired Rubicon Genomics, Inc. (Rubicon) in January 2017, the acquisition was aimed at expanding the product portfolio in next generation sequencing sample preparation. TBUSH also completed its acquisition of WaferGen Bio-systems, Inc. (WaferGen) in March 2017.

Some of the other key players operating in this industry include Merck KGaA, Genscript Biotech Corporation, Agilent Technologies, Inc., Promega Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., New England Biolabs Inc., and Lonza Group Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook
Posted by at 1 comment:
Labels: , , , ,
Location: United States
Subscribe to: Posts (Atom)